<DOC>
	<DOCNO>NCT00321594</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose belinostat see well work treat patient liver cancer remove surgery . Belinostat may stop growth tumor cell block enzymes need cell growth</brief_summary>
	<brief_title>Belinostat Treating Patients With Liver Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose-limiting toxicity ( DLT ) establish maximum tolerate dose ( MTD ) PXD101 ( belinostat ) patient unresectable hepatocellular carcinoma ( HCC ) . ( Phase I ) II . Assess pharmacokinetic profile PXD101 patient . ( Phase I ) III . Assess tumor response patient treated drug . ( Phase II ) OUTLINE : This multicenter , dose-escalation phase I study follow phase II study . PHASE I : Patients receive belinostat intravenously ( IV ) 30 minute day 1-5 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos belinostat maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PHASE II : Patients receive belinostat ( phase I ) MTD determine phase I . After completion study therapy , patient follow 8 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>Histologically cytologically confirm hepatocellular carcinoma amenable curative resection Measurable disease , define ≥ 1 lesion accurately measure ≥ 1 dimension ( long diameter record ) ≥ 20 mm conventional technique OR ≥ 10 mm MRI spiral CT scan No known brain metastases No clinical ascites encephalopathy Life expectancy &gt; 12 week ECOG performance status ( PS ) 02 Karnofsky PS 60100 % WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.7 mg/dL Albumin ≥ 2.8 mg/dL ALT ≤ 5.0 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 6 time ULN Prothrombin time ≤ 4 sec ULN Creatinine ≤ 1.6 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient use effective contraception No Child'sPugh 's grade Class C hepatic impairment No history allergic reaction attribute compound similar chemical biologic composition PXD101 No mark baseline prolongation QT/QTc interval , include follow : Repeated demonstration QTc interval &gt; 500 msec Long QT Syndrome No ongoing active infection No significant cardiovascular disease , include follow : Unstable angina pectoris Uncontrolled hypertension Congestive heart failure relate primary cardiac disease Condition require antiarrhythmic therapy Ischemic severe valvular heart disease Myocardial infarction within past 6 month No psychiatric illness social situation would preclude study compliance No uncontrolled illness More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) recover More 4 week since prior radiotherapy recover At least 2 week since prior valproic acid No concurrent combination antiretroviral therapy HIVpositive patient No concurrent participation another investigational study No concurrent investigational agent No concurrent anticancer therapy No concurrent use follow : Disopyramide Dofetilide Ibutilide Procainamide Quinidine Sotalol Bepridil Amiodarone Arsenic trioxide Cisapride Calcium channel blocker ( e.g. , lidoflazine ) Clarithromycin Erythromycin Halofantrine Pentamidine Sparfloxacin Domperidone Droperidol Chlorpromazine Haloperidol Mesoridazine Thioridazine Pimozide Methadone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>